CHICAGO -- A bumetanide nasal spray in development for heart failure was well-tolerated and showed reliable rates of absorption compared with oral and intravenous delivery in a phase I trial of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback